



Transparency notification

Brussels (Belgium), 17 November 2016 – 20:00 (CEST) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 14 November 2016, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.).

BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV had decreased and has crossed downward the 3% threshold.

On 11 November 2016, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 749 621 UCB shares with voting rights (versus 6 030 756 UCB shares in its previous notification dated 3 November 2016), representing 2.96% of the total number of shares issued by the company (194 505 658) (versus 3.10% in the notification dated 3 November 2016).

2. Content of the notification

The transparency notification dated 14 November 2016 included the following information:

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
BlackRock, Inc	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Asset Management Deutschland AG	Max-Joseph-Straße 6, Munich, 80333, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock International Limited	Exchange Place One, 1 Sempole Street, Edinburgh, EH3 8BL, U.K.
BlackRock Investment Management (Australia) Limited	Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan

- **Date on which the threshold is crossed:** 10 November 2016.
- **Threshold crossed (in %):** 3%.
- **Denominator:** 194 505 658.
- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
BlackRock, Inc	0	0		0,00%	
BlackRock (Netherlands) B.V.	19.816	19.816		0,01%	
BlackRock (Singapore) Limited	8.434	8.434		0,00%	
BlackRock Advisors (UK) Limited	1.010.380	897.386		0,46%	
BlackRock Advisors, LLC	49.520	48.862		0,03%	
BlackRock Asset Management Canada Limited	61.026	61.026		0,03%	
BlackRock Asset Management Deutschland AG	205.399	179.996		0,09%	
BlackRock Asset Management North Asia Limited	644	644		0,00%	
BlackRock Capital Management, Inc.	457	0		0,00%	
BlackRock Financial Management, Inc.	88.225	64.915		0,03%	
BlackRock Fund Advisors	1.832.182	1.826.581		0,94%	
BlackRock Institutional Trust Company, National Association	1.927.991	2.012.649		1,03%	
BlackRock International Limited	15.564	15.564		0,01%	
BlackRock Investment Management (Australia) Limited	41.755	41.755		0,02%	
BlackRock Investment Management (UK) Limited	271.177	151.987		0,08%	
BlackRock Investment Management, LLC	318.516	240.336		0,12%	
BlackRock Japan Co., Ltd.	179.670	179.670		0,09%	
Subtotal	6.030.756	5.749.621		2,96%	
TOTAL		5.749.621	0	2,96%	0,00%

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
BlackRock Advisors (UK) Limited	Securities Lent			115.874	0,06%	physical
BlackRock Asset Management Deutschland AG	Securities Lent			31.000	0,02%	physical
BlackRock Fund Advisors	Securities Lent			112	0,00%	physical
BlackRock Institutional Trust Company, National Association	Securities Lent			42.304	0,02%	physical
BlackRock Investment Management (UK) Limited	Securities Lent			3.200	0,00%	physical
BlackRock Institutional Trust Company, National Association	Contract for Difference			114.083	0,06%	cash
BlackRock International Limited	Contract for Difference			18.432	0,01%	cash
BlackRock Investment Management (UK) Limited	Contract for Difference			264.024	0,14%	cash
TOTAL				589.029	0,30%	

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	6.338.650	3,26%

- **Chain of controlled undertakings through which the holding is effectively held:**

Please see the full chain of control in the PDF which is attached to this press release.

- **Additional information:**

The disclosure obligation arose due to voting rights for BlackRock, Inc. going below 3%.

3. Further information

This press release and the detailed transparency notification is available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news